Literature DB >> 18990066

New generation of inactivated poliovirus vaccines for universal immunization after eradication of poliomyelitis.

Konstantin Chumakov1, Ellie Ehrenfeld.   

Abstract

Twenty years of global polio eradication efforts may soon eliminate the transmission of wild-type poliovirus. However, new information that has been learned about poliovirus, as well as the political realities of a modern world, demand that universal immunity against poliomyelitis be maintained, even after wild-type poliovirus is eradicated. Although 2 excellent vaccines have proven to be highly effective in the past, neither the live-attenuated vaccine nor the currently used inactivated vaccine are optimal for use in the posteradication era. Therefore, concerted efforts are urgently needed to develop a new generation of vaccine that is risk-free and affordable and can be produced on a global scale. Here, we discuss the desired properties of a vaccine and methods to create a new polio vaccine.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18990066      PMCID: PMC2596976          DOI: 10.1086/593310

Source DB:  PubMed          Journal:  Clin Infect Dis        ISSN: 1058-4838            Impact factor:   9.079


  53 in total

Review 1.  Inactivation of viruses by aziridines.

Authors:  F Brown
Journal:  Vaccine       Date:  2001-11-12       Impact factor: 3.641

2.  Progress with inactivated poliovirus vaccines derived from the Sabin strains.

Authors:  Y Doi; S Abe; H Yamamoto; H Horie; H Ohyama; K Satoh; Y Tano; Y Ota; M Miyazawa; K Wakabayashi; S Hashizume
Journal:  Dev Biol (Basel)       Date:  2001

3.  The effect of mass peroral immunisation by live vaccines from Sabin strains on the epidemiological process of poliomyelitis.

Authors:  M P CHUMAKOV
Journal:  J Hyg Epidemiol Microbiol Immunol       Date:  1960

4.  Long-term excretion of vaccine-derived poliovirus by a healthy child.

Authors:  Javier Martín; Kofi Odoom; Gráinne Tuite; Glynis Dunn; Nicola Hopewell; Gill Cooper; Catherine Fitzharris; Karina Butler; William W Hall; Philip D Minor
Journal:  J Virol       Date:  2004-12       Impact factor: 5.103

5.  Quasispecies diversity determines pathogenesis through cooperative interactions in a viral population.

Authors:  Marco Vignuzzi; Jeffrey K Stone; Jamie J Arnold; Craig E Cameron; Raul Andino
Journal:  Nature       Date:  2005-12-04       Impact factor: 49.962

Review 6.  Vaccines: correlates of vaccine-induced immunity.

Authors:  Stanley A Plotkin
Journal:  Clin Infect Dis       Date:  2008-08-01       Impact factor: 9.079

7.  Immunisation against poliomyelitis: moving forward.

Authors:  Ellie Ehrenfeld; Roger I Glass; Vadim I Agol; Konstantin Chumakov; Walter Dowdle; T Jacob John; Samuel L Katz; Mark Miller; Joel G Breman; John Modlin; Peter Wright
Journal:  Lancet       Date:  2008-04-19       Impact factor: 79.321

8.  Internal ribosomal entry site substitution eliminates neurovirulence in intergeneric poliovirus recombinants.

Authors:  M Gromeier; L Alexander; E Wimmer
Journal:  Proc Natl Acad Sci U S A       Date:  1996-03-19       Impact factor: 11.205

Review 9.  Epidemiology of poliomyelitis in the United States one decade after the last reported case of indigenous wild virus-associated disease.

Authors:  P M Strebel; R W Sutter; S L Cochi; R J Biellik; E W Brink; O M Kew; M A Pallansch; W A Orenstein; A R Hinman
Journal:  Clin Infect Dis       Date:  1992-02       Impact factor: 9.079

Review 10.  Polio eradication: the OPV paradox.

Authors:  Walter R Dowdle; Esther De Gourville; Olen M Kew; Mark A Pallansch; David J Wood
Journal:  Rev Med Virol       Date:  2003 Sep-Oct       Impact factor: 6.989

View more
  10 in total

1.  Fluorescence correlation spectroscopy as a sensitive and useful tool for revealing potential overlaps between the epitopes of monoclonal antibodies on viral particles.

Authors:  Ludovic Richert; Nicolas Humbert; Eric Larquet; Yves Girerd-Chambaz; Catherine Manin; Frédéric Ronzon; Yves Mély
Journal:  MAbs       Date:  2016-07-18       Impact factor: 5.857

2.  Chimpanzee-human monoclonal antibodies for treatment of chronic poliovirus excretors and emergency postexposure prophylaxis.

Authors:  Zhaochun Chen; Konstantin Chumakov; Eugenia Dragunsky; Diana Kouiavskaia; Michelle Makiya; Alexander Neverov; Gennady Rezapkin; Andrew Sebrell; Robert Purcell
Journal:  J Virol       Date:  2011-02-23       Impact factor: 5.103

3.  A mucosal adjuvant for the inactivated poliovirus vaccine.

Authors:  Benjamin P Steil; Patricia Jorquera; Janny Westdijk; Wilfried A M Bakker; Robert E Johnston; Mario Barro
Journal:  Vaccine       Date:  2013-12-13       Impact factor: 3.641

4.  Genetic inactivation of poliovirus infectivity by increasing the frequencies of CpG and UpA dinucleotides within and across synonymous capsid region codons.

Authors:  Cara C Burns; Ray Campagnoli; Jing Shaw; Annelet Vincent; Jaume Jorba; Olen Kew
Journal:  J Virol       Date:  2009-07-15       Impact factor: 5.103

5.  RCDI/eRCDI: a web-server to estimate codon usage deoptimization.

Authors:  Pere Puigbò; Lluís Aragonès; Santiago Garcia-Vallvé
Journal:  BMC Res Notes       Date:  2010-03-31

Review 6.  Rationalizing the development of live attenuated virus vaccines.

Authors:  Adam S Lauring; Jeremy O Jones; Raul Andino
Journal:  Nat Biotechnol       Date:  2010-06-07       Impact factor: 54.908

Review 7.  Future of polio vaccines.

Authors:  Ellie Ehrenfeld; John Modlin; Konstantin Chumakov
Journal:  Expert Rev Vaccines       Date:  2009-07       Impact factor: 5.217

Review 8.  From emergence to eradication: the epidemiology of poliomyelitis deconstructed.

Authors:  Neal Nathanson; Olen M Kew
Journal:  Am J Epidemiol       Date:  2010-10-26       Impact factor: 4.897

Review 9.  T Cell Immunity To Enterovirus 71 Infection In Humans And Implications For Vaccine Development.

Authors:  Pinn Tsin Isabel Yee; Chit Laa Poh
Journal:  Int J Med Sci       Date:  2018-07-25       Impact factor: 3.738

10.  Emergence and re-emergence of viral diseases of the central nervous system.

Authors:  Diane E Griffin
Journal:  Prog Neurobiol       Date:  2009-12-10       Impact factor: 11.685

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.